Courses

Update on the Safety and Efficacy of JAK Inhibitor Therapeutics for the Treatment of Atopic Dermatitis

Update on the Safety and Efficacy of JAK Inhibitor Therapeutics for the Treatment of Atopic Dermatitis

This CME program will provide clinicians with an update regarding the safety and efficacy of JAK inhibitor therapeutics for the treatment of atopic dermatitis. The expert faculty, led by Dr. Lawrence F. Eichenfield, will first outline current clinical trial data for JAK-1 inhibitor therapeutics in atopic dermatitis (AD), encompassing topics such as difficulties living with AD and the unmet needs ...
View Course
The Impact of the COVID Pandemic on Continuity of Care and Adherence to DAPT Among Patients with CAD/ACS/PCI

The Impact of the COVID Pandemic on Continuity of Care and Adherence to DAPT Among Patients with CAD/ACS/PCI

Areas of North America and Western Europe have struggled with repeated waves and emerging variants of SARS CoV-2 infection. Even as some countries and regions strive to return to pre-pandemic behavior, the COVID-19 pandemic continues to exert many deleterious effects on the delivery of continuing healthcare for many vulnerable populations. Those affected include patients who would be expected to benefit ...
View Course
Advances in Biomarkers and Anti BCMA Therapeutics to Improve Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

Advances in Biomarkers and Anti BCMA Therapeutics to Improve Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

This CME/CE program will highlight recent advances in the treatment and management of patients with relapsed/refractory multiple myeloma (RRMM). The expert faculty, led by C. Ola Landgren, MD, will first discuss best practices for integrating BCMA-targeted therapy into treatment plans for patients with RRMM. Following, emerging therapies in relapsed and remitting multiple myeloma will be reviewed, analyzing both current options ...
View Course
Optimal Guideline Directed Medical Therapy for Heart Failure

Optimal Guideline Directed Medical Therapy for Heart Failure

This CME/CE program will highlight optimal guideline directed medical therapy for patients with heart failure (HF). The expert faculty will first review current ACC/AHA and ESC recommendations for directed medical therapy to treat patients with heart failure with reduced ejection fraction (HFrEF). Following, the faculty will analyze clinical trial data for SGLT2is, vericiguat, and omecamtiv mecarbil therapeutics. Next, clinical strategies ...
View Course
Therapeutic Advances in the Management of Patients with Gastrointestinal Cancer

Therapeutic Advances in the Management of Patients with Gastrointestinal Cancer

This CME post-conference review and analysis will highlight therapeutic advances in the management of patients with gastrointestinal cancer, including data presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022. The expert faculty will analyze the latest therapeutic advances for the treatment and management of gastrointestinal (GI) cancer as presented at ASCO GI 2022. They will also ...
View Course

Mineralocorticoid Receptor Antagonism In Patients on Hemodialysis

Welcome to this AcademicCME Nephrology Network Program. These “quick hitting” programs focus on a visual comparison between two important studies in a single issue of importance to those clinicians who care for the kidneys and the patients in which those kidneys live. This Nephrology Network program is accredited for up to 1.5hr CME (physicians) and CE (nurses, NPs, PAs, pharmacists) ...
View Course

The MS Patient Perspective

Join Dr. Stephen Krieger (@SKriegerMD), a Professor Neurology at the Corinne Goldsmith Dickinson Center for MS at Mount Sinai, in a unique CE/CME-accredited video. Dr. Krieger sits down for an honest 1:1 conversation with one of his first patients, Kate Milliken, with whom he has had a doctor-patient relationship for 15 years. They discuss how considering the patient’s perspective is ...
View Course
Applying JAK Inhibitor Therapeutics to Improve Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis

Applying JAK Inhibitor Therapeutics to Improve Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis

This CME/CE program is derived from content presented at the Maui Derm for Dermatologists 2022 Annual Meeting. The expert faculty, led by Lawrence Eichenfield, MD, will highlight the use of Janus kinases (JAK) inhibitor therapeutics to improve outcomes in patients with atopic dermatitis. The faculty will begin with an overview of current clinical trial data, including new and emerging therapies ...
View Course

Advances in the Management of Patients with Metastatic Breast Cancer

Advances in the Management of Patients with Metastatic Breast Cancer

This CME/CE program will outline recent advances in the treatment and management of patients with metastatic breast cancer. The expert faculty, led by Dr. Harold J. Burstein, will first cover ER-positive breast cancer, analyzing data for CDK 4/6 inhibitors, ER targeting agents and antibody drug conjugates. Following, pertinent information regarding triple negative breast cancer will be reviewed, highlighting clinical implication ...
View Course
Advances in Disease Management of Generalized Myasthenia Gravis by Reducing Levels of IgG Autoantibodies

Advances in Disease Management of Generalized Myasthenia Gravis by Reducing Levels of IgG Autoantibodies

This CME/CE program will highlight recent advances in disease management of generalized myasthenia gravis (MG) by reducing levels of IgG autoantibodies. The expert faculty, led by Dr. James F. Howard, will first cover the pathophysiology of MG, including therapeutic approaches and general limitations for current immunosuppressant therapies. Following, current clinical trial data of FcRn Inhibitors in myasthenia gravis will be ...
View Course